David Low

Money Moves

As of September 2026: Buy rating on Telix, A$22.00 target

Telix Pharmaceuticals, an Australian maker of cancer imaging and treatment agents, agreed on September 21 to buy German isotope producer ITM Isotope Technologies Munich. The deal is worth up to $2.35 billion all-in, with $1.65 billion paid upfront, most of it in Telix shares.

Updated Sep 21